Bristol-Myers Squibb (BMS) and Boehringer Ingelheim (BI) will extend their voluntary discounts, rebates and price freezes to all state AIDS Drug Assistance Programs (ADAPs) through 2014, according to a statement by the ADAP Crisis Task Force, which secured the deal, and the National Alliance of State and Territorial AIDS Directors (NASTAD), which convened the group. AbbVie, Gilead Sciences, Janssen Therapeutics, Merck and ViiV Healthcare had previously reached similar agreements.

To read the statement, click here.